256 Newsroom — Uganda's Digital News Infrastructure
Business

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction. - Barron's

Published by Barron's By Mackenzie Tatananni · 17 August 2026 at 21:37
Share
EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction. - Barron's
Image · Barron's

What the report says

Duravyu, EyePoint’s candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.

Read the full report at Barron's →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

Absa calls for investment execution to drive Uganda’s next growth cycleNile Post 256 Newsroom Zawadi shuts down buses over Shs1.7b Stanbic Bank loan, disrupting transport in Adjumani - Daily MonitorDaily Monitor Uganda Is Producing More, But Who Is Buying What We Make?Nile Post Sanjay Tanna urges value addition at Equity Bank trade roadshowThe Independent Uganda 256 Newsroom UIA: French Firms Have Committed $4 Bn to Uganda, But Trade Lags - ChimpReportsChimpReports 256 Newsroom dfcu’s Gloria Namutebi: Financing the Assets That Move Uganda’s Economy - ChimpReportsChimpReports